期刊文献+

c-Myc和VEGF基因的小分子干扰RNA对人结直肠癌细胞的影响 被引量:3

Effect of siRNA targeting c-Myc and VEGF on human coiorectal cancer cells
原文传递
导出
摘要 目的研究靶向c-Myc和血管内皮生长因子(VEGF)基因的小分子干扰RNA(siRNA)表达质粒对人结直肠癌细胞株的影响。方法设计靶向c-Myc和VEGF的特异性siRNA。应用体内载体表达法合成其表达质粒.转染人结直肠癌细胞株Volo后.以Westernblot检测c-Myc和VEGF的蛋白表达;以MTT、流式细胞术、TUNEL染色分析、基质胶侵袭实验检测细胞增殖活性、凋亡特性、细胞周期分布及侵袭能力的改变。结果酶切及DNA测序证实c—Myc和VEGF的siRNA表达质粒均构建成功。转染细胞后,与对照组相比较。重组质粒组细胞c-Myc和VEGF的蛋白表达水平显著下调明显(均P〈0.01)。重组质粒c—Myc组、VEGF组和c—Myc加VEGF组细胞增殖抑制率分别为(59.20±5.05)%、(32.31±3.48)%和(75.81±7.89)%:细胞凋亡率分别为(40.50±4.37)%、(21.30±2.98)%和(62.59±9.66)%,均显著高于对照组[细胞增殖抑制率(6.80±1.45)%;细胞凋亡率(2.90±0.36)%;均P〈0.05]。重组质粒VEGF组和c—Myc加VEGF组的细胞侵袭率分别为(7.34±3.65)%和(2.80±1.02)%,明显低于对照组的(18.57±7.46)%(P〈0.05)。其中,重组质粒c-Myc加VEGF组细胞增殖、调亡及侵袭性的改变最为显著,明显高于另外两个重组质粒组(均P〈0.05)。结论特异性siRNA有效抑制了人结直肠癌Volo细胞c—Myc和VEGF的表达.从而抑制了肿瘤细胞的增殖活性和侵袭性.并诱导细胞凋亡.两者具有协同作用。 Objective To investigate the biological behavioral effects of specific siRNA expression plasmids targeted against c-Myc and vascular endothelial growth factor (VEGF) on human colorectal cancer cell line Volo. Methods The expression plasmids with small interfering RNA (siRNA) aiming at c-Myc and VEGF were designed and constructed respectively, then transfected into Volo cells by eukaryocyte transfection technique. The protein expressions of c-Myc and VEGF were detected by Western blotting. Cellular proliferation, apoptosis, cycle distribution and invasion character were analyzed by tetrazolium bromide colorimetry(MTT), flow cytometry (FCM), TUNEL assay and matrigel invasion assay respectively. Results Enzymatic digestion and DNA sequencing confirmed that the c-Myc and VEGF specific siRNA expression plasmids were constructed successfully. After plasmids were transfected into cells, the protein expressions of c-Myc and VEGF were significantly downregulated respectively as compared with control group (P〈0.01). The cellular proliferation inhibitory rates in c-Myc siRNA group, VEGF siRNA group and c-Myc+VEGF group were (59.20±5.05)%, (32.31±3.48)% and (75.81±7.89)% respectively, which were higher than that in control group [(6.80±1.45)%](all P〈0.05). The cell apoptosis rate in above 3 groups were (40.50±4.37)%, (21.30±2.98)% and (62.59±9.66)% respectively, which were higher than that in control group [ (2.90±0.36)%] (all P〈0.05). The cell invasion rates in VEGF siRNA group and c-Mye+VEGF siRNA group were(7.34±3.65)% and(2.80±1.02)%, which were lower than that in control group[(18.57±7.46)%](P〈0.05). The effect of c-Myc+VEGF siRNA group was greater. Conclusions The specific siRNA efficiently silences the expression of c-Myc and VEGF, subsequently, suppresses the cell proliferation, triggers the cell apoptosis and inhibits the cell invasiveness in these transfected colorectal cancer Volo cells. In addition, the synergism of siRNA-c-Myc and siRNA-VEGF in transfected cells can be found.
出处 《中华胃肠外科杂志》 CAS 北大核心 2009年第5期502-506,共5页 Chinese Journal of Gastrointestinal Surgery
关键词 结直肠肿瘤 基因 C-MYC 血管内皮生长因子 小分子干扰RNA 人结直 肠细胞株 Colorectal neoplasms Gene c-Myc Vascular endothelial growth factor Small interfering RNA Human colorectal cancer volo cells line
  • 相关文献

参考文献13

  • 1黄玉宝,卿三华,叶长生.结直肠癌生物学基础及其靶点药物治疗研究进展[J].中华胃肠外科杂志,2008,11(3):294-296. 被引量:1
  • 2Saif MW.Targeted agents for adjuvant therapy of colon cancer.Clin Colorectal Cancer,2006,6(1):46-51.
  • 3Willett CG,Duda DG,Czito BG,et al.Targeted therapy in rectal cancer.Oncology(Williston Park),2007,21(9):1055-1065.
  • 4Chu EC,Chai J,Ahluwalia A,et al.Mesalazine downregulates c-Myc in human colon cancer cells.A key to its chemopreventive action? Aliment Pharmacol Ther,2007,25(12):1443-1449.
  • 5Binion DG,Otterson MF,Rafiee P.Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition.Gut,2008,57(11):1509-1517.
  • 6Gartel AL,Shchors K.Mechanisms of c-Myc-mediated transcriptional repression of growth arrest genes.Exp Cell Res,2003,283(1):17-21.
  • 7Sansom OJ,Meniel VS,Muncan V,et al.Myc deletion rescues Apc deficiency in the small intestine.Nature,2007,446(7136):676-679.
  • 8Wilkins JA,Sansom OJ.C-Myc is a critical mediator of the phenotypes of Apc loss in the intestine.Cancer Res,2008,68(13):4963-4966.
  • 9Díaz-Rubio E.Vascular endothelial growth factor inhibitors in colon cancer.Adv Exp Med Biol,2006,587:251-275.
  • 10常家聪,魏宜胜,刘弋,张红,王道兵,陈向红.血管内皮生长因子D和微淋巴管密度及微血管密度与直肠癌进展的关系[J].中华胃肠外科杂志,2008,11(4):367-370. 被引量:8

二级参考文献39

  • 1王玉珍,梁志清,龙玲,王丹.血管内皮生长因子C、D在上皮性卵巢癌的表达及与腹股沟和腹膜后淋巴结转移的关系[J].第三军医大学学报,2004,26(11):977-980. 被引量:8
  • 2许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1365
  • 3綦晓龙,傅仲学,邓靖宇.血管内皮生长因子C及其受体3在直肠癌组织中的表达及其临床意义[J].中华胃肠外科杂志,2004,7(5):407-410. 被引量:7
  • 4Cho CD, Fisher GA, Halsey J, et al. Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies, Invest New Drugs, 2006,24. 117-123.
  • 5Kuo T, Cho CD, Halsey J, et al. Phase Ⅱ study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol, 2005,23 : 5613-5619.
  • 6Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol, 2008,26:374-379.
  • 7Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst, 2001,93: 1062-1074.
  • 8Crul M, de Klerk GJ, Beijnen JH, et al. Ras biochemistry and farnesyl transferase inhibitors: a literature survey. Anticancer Drugs, 2001,12: 163-184.
  • 9Rao S, Cunningham D, de Gramont A, et al. Phase Ⅲ double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol, 2004,22:3950-3957.
  • 10Hilger RA, Kredke S, Hedley D, et al. ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006. Int J Clin Pharmacol Ther, 2002,40 : 567-568.

共引文献7

同被引文献56

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部